Aug 01, 2024 8:20am EDT DiaMedica Therapeutics to Provide a Business Update and Report Second Quarter 2024 Financial Results August 8, 2024
Jul 11, 2024 8:00am EDT DiaMedica Therapeutics Releases Preeclampsia White Paper and Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia
Jun 26, 2024 8:00am EDT DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia
May 08, 2024 4:30pm EDT DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results
May 02, 2024 8:55am EDT DiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024
Apr 17, 2024 4:08pm EDT DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
Mar 19, 2024 4:15pm EDT DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results
Jan 29, 2024 4:13pm EST DiaMedica Therapeutics Announces Poster Presentation at International Stroke Conference
